Target $25
Thursday, December 5, 2019
Lexicon up on positive early-stage data on neuropathic pain candidate LX9211
Lexicon Pharmaceuticals (LXRX +4%) is up on below-average volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers.
LX9211 demonstrated a favorable safety profile and pharmacokinetic activity supportive of once-daily dosing. The most common adverse events were headache and dizziness.
Small molecule LX9211 inhibits an enzyme called adaptor-associated protein kinase 1 (AAK1). The company acquired exclusive rights from development partner Bristol-Myers Squibb two years ago.
Development is ongoing.
FDA OKs new MRSA test from Roche
The FDA approves Roche’s (OTCQX:RHHBY -0.1%) cobas vivoDx MRSA diagnostic test to detect methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization in nasal swab samples.
Results from the bioluminescence assay are generated in as little as five hours.
Biogen’s aducanumab showed mixed results in Alzheimer’s studies
Results from two Phase 3 clinical trials, EMERGE and ENGAGE, evaluating Biogen’s (BIIB -2.9%) aducanumab in patients with early Alzheimer’s disease (AD) produced different outcomes. The data were presented at the Clinical Trials on Alzheimer’s Disease Conference in San Diego.
In EMERGE, the high dose arm met the primary endpoint of the change from baseline in CDR-SB score at week 78 compared to placebo (p=0.0101) and well as the secondary endpoints of ADAS-Cog 13 and ADCS-ADL-MCI at week 78. The other secondary endpoint, MMSE score, was not met in the larger dataset analysis but did based on the final dataset (p=0.0493). The low dose arm missed all endpoints.
In ENGAGE, both the low dose and high dose arms failed to achieve the primary and all secondary endpoints in either dataset.
The company plans to file a U.S. application based on the totality of the data.
Cerner ramps up cybersecurity efforts with new partnership: 3 things to know
Cerner is teaming up with Cybereason, a cyber defense platform developer, to help healthcare providers address cybersecurity vulnerabilities and digital threats to their organizations, according to a Dec. 4 news release.
Three things to know:
1. Through the partnership, Cybereason will integrate its platform with Cerner’s software to help the EHR vendor’s clients streamline their respective cybersecurity infrastructures.
2. Cerner and Cybereason also plan to create a go-to-market strategy to provide remediation efforts for incidents detected through Cerner’s cyber consulting advisory services.
3. Cerner and Cybereason’s collaboration aims to address growing IT security risks, which have left healthcare organizations tasked with better securing their information systems, devices and data.
“Today our clients deliver care in a connected and digital way, a revolution that has contributed to safer and more efficient care,” said Jay Saviano, senior director of security solutions at Cerner, according to the news release. “With these technological advancements, it’s essential that every health system have robust digital security strategies.”
Warren bill would block $40B+ companies making acquisitions: 5 things to know
A Senate anti-monopoly bill is in the works that could transform the health system landscape, reviewing past megamergers and banning them entirely for companies with revenue over $40 billion, Bloomberg reports.
Democratic presidential candidate Sen. Elizabeth Warren, D-Mass., is drafting the proposal, according to the report. Here are five quick takeaways for healthcare leaders, based on the Bloomberg review of the draft bill:
1. Mergers that involve a company with annual revenues of $40 billion or more will be banned.
2. Mergers that involve companies with combined sales over $15 billion will be banned.
3. Some exceptions to this ban will include companies at risk of bankruptcy.
4. The legislation would also consider the effect a transaction would have on entrepreneurs, innovation, privacy and workers, banning, for example, noncompete and no-poaching agreements.
5. Bloomberg writes that the law will likely face significant hurdles in Congress.
Subscribe to:
Comments (Atom)